HAD and the need for new trial design methodology

AIDS

Volumn 21, Issue 14, 2007, Pages 1965-1966

  Brew, Bruce James ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Xavier Building ^*  (Australia)

Author keywords

AIDS dementia; Biomarkers; Clinical trials

Indexed keywords

ANTIRETROVIRUS AGENT; MEMANTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; METHODOLOGY; PREVALENCE; PRIORITY JOURNAL;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CLINICAL TRIALS; COGNITION DISORDERS; HUMANS; RESEARCH DESIGN;

EID: 34548282699     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328133850e     Document Type: Editorial

References (16)

1. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13:1249-1253.
2. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999; 13:1889-1897.
3. Dore GJ, McDonald A, Li Y, Kaldor J, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 2003; 17:1539-1545.
4. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in HIV/AIDS infection across pre-HAART and HAART eras: a combined study of 2 cohorts. J Neurovirol 2004; 10:350-357.
5. Dougherty RH, Skolasky RL Jr, McArthur JC. Progression of HIV-associated dementia treated with HAART. AIDS Read 2002; 12:69-74.
6. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10:317-331.
7. Brew BJ. Evidence for a change in AIDS dementia complex (ADC) in the era of highly active antiretroviral therapy and the possibility of new forms of ADC. AIDS 2004; 18 (Suppl 1): S75-S78.
8. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 2006; 111:529-538.
9. Brew BJ. Markers of AIDS dementia complex: the role of cerebrospinal fluid assays. AIDS 2001; 15:1883-1884.
10. Brew BJ, Halman M, Catalan J, Sacktor N, Price RW, Brown S, et al. Factors in AIDS dementia complex trial design: results and lessons from the Abacavir Trial. PLoS Clin Trials 2007 (in press).
11. McArthur JC, McDermott MP, McClernon D, St Hillaire C, Conant K, et al. Attenuated CSF infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004; 61:1687-1696.
12. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006; 66:1447-1450.
13. Cysique LA, Brew BJ, Halman M, Catalan J, Sacktor N, et al. Undetectable cerebrospinal fluid HIV viral load does not indicate inactive AIDS dementia complex. J Acquir Immune Defic Syndr 2005; 39:426-429.
14. Gisslen M, Rosengren L, Hagberg L, Deeks SG, Price RW. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther 2005; 2:6.
15. Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, et al. Cerebrospinal fluid neurofilament protein (NFL) - a Marker of AIDS dementia complex. J Neurol 2007 (in press).
16. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. Cerebrospinal fluid amyloid β42 and Tau levels correlate With AIDS dementia complex. Neurology 2005; 65:1490-1492.